Story
FuelCell Energy Stock Surges on Bullish Oppenheimer Initiation

Summary
Shares of FuelCell Energy (FCEL) rose sharply after Oppenheimer initiated coverage with an Outperform rating and a $24 price target, citing the firm's potential to power the data center industry.
Shares of FuelCell Energy (NASDAQ:FCEL) surged in pre-market trading on Monday after investment bank Oppenheimer initiated coverage on the stock with a bullish rating, highlighting the company's strategic position to supply power to the booming data center sector.
Oppenheimer Sets High Target
Oppenheimer began its coverage of FuelCell with an Outperform rating and a $24.00 price target. According to Investing.com, this target implies substantial upside from the stock's previous closing price of $16.14. In pre-market activity, the stock climbed 7.8% to trade around $17.40.
The firm's analysis frames FuelCell as a "differentiated provider of firm, continuous, on-site power." Oppenheimer argued this profile is uniquely suited to meet the surging infrastructure demands of data center operators, who face structurally constrained power supplies.
Growth Plans and Revenue Visibility
Central to Oppenheimer's positive thesis is FuelCell's ambitious production capacity expansion plan. The company is targeting an annual output of 500 MW by fiscal year 2029, a more than tenfold increase from its fiscal 2026 production rate.
AdOppenheimer also noted that a multi-billion-dollar project backlog provides significant revenue visibility for the company. The bank expects project economics to improve as FuelCell scales its manufacturing operations.
Market Context and Investor Sentiment
The initiation from Oppenheimer adds to growing analyst attention on the company. Craig-Hallum also recently launched coverage with a Buy rating, and Jefferies maintains a Buy stance. This bullish sentiment was recently reinforced by an insider transaction in mid-September, when a company director purchased approximately $247,000 worth of shares on the open market.
Monday's stock move came after a nearly 10% pullback in the prior week, making the new price target particularly notable for investors. While the pre-market price is well above the 52-week low of $5.71, it remains a considerable distance from its 52-week high of $37.88.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.